Strategies for IND Filing Success: Chemistry, Manufacturing and Controls

October 21, 2016

Presented by:

Sharon Ayd, Ph.D., MBA
Chief Scientific Officer and SVP, Pharmaceuticals
Presentation Outline

- Background
- High Level CMC Contents Overview
- CMC Detail vs. Clinical Development Stage
- Summary
- References
Background
FDA Regulation of Clinical Trials

With ….the Prescription Drug User Fee Act of 1992 (PDUFA) review action performance goals, and the resulting significant declines in mean and median time ….attention has turned to increasing the efficiency of other components of the drug development process….. One part of IND regulation of particular interest …. is the regulation of the initial testing of drugs in humans (i.e., Phase 1 trials).

This guidance* clarifies requirements for data and data presentation in 21 CFR 312.22 and 312.23 related to the initial entry into human studies in the United States of an investigational drug, including well-characterized, therapeutic, biotechnology-derived products. Present regulations allow a great deal of flexibility in the amount and depth of various data to be submitted in an IND depending in large part on the phase of investigation and the specific human testing being proposed…..

* Guidance For Industry: Content and Format for INDs for Phase 1 Studies of Drugs Including Well Characterized Therapeutic, Biologically Derived Products, CDER, CBER, November 1995
Guidances (Drugs)

- The category “Chemistry, Manufacturing and Controls” has been renamed Pharmaceutical Quality/CMC
  - The guidance document entitled "Submitting Documentation for the Manufacturing of and Controls for Drug Products" was withdrawn 4/14/2015.

- This guidance was withdrawn because many of the recommendations were obsolete and have been more recently addressed in FDA and ICH guidance documents, including, but not limited to;
  - Content and Format for INDs for Phase 1 Studies of Drugs Including Well Characterized Therapeutic, Biologically Derived Products
  - INDs for Phase 2 and Phase 3 Studies: Chemistry, Manufacturing, and Controls Information
  - Q2A Text on Validation of Analytical Procedures
  - Q2B Validation of Analytical Procedures: Methodology
  - Q3C Impurities: Residual Solvents
  - Q6A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances
  - M4: The CTD -- Quality
Disclaimers

• This presentation:
  – Is applicable to small chemical entities
  – Excludes novel therapeutic chemical entities
  – Excludes biologically derived therapeutic agents
  – Excludes botanical therapeutic agents
  – Excludes therapeutic agents derived from natural sources
High Level
CMC Contents Overview
Pharmaceutical Quality/CMC

Drug Substance Information Needed

- A description of the drug substance, including its physical, chemical, or biological characteristics
- The name and address of its manufacturer
- The general method of preparation of the drug substance
- The acceptable limits and analytical methods used to assure the identity, strength, quality, and purity of the drug substance
- Information to support the stability of the drug substance during the toxicology studies and the proposed clinical trial(s)
Pharmaceutical Quality/CMC
Drug Product Information Needed

- List of components, including alternatives for inactive compounds used to manufacture investigational drug product, including those intended to appear in the drug product and those which may not appear, but are used in the manufacturing process.
- Where applicable, the quantitative composition of the investigational new drug product, including any reasonable variations that may be expected during the investigational stage.
- The name and address of the drug product manufacturer.
- General description of manufacturing & packaging procedures appropriate for product.
- The limits & analytical methods for identity, strength, quality, and purity of the drug product.
- Information for stability of drug substance during the toxicological studies and proposed clinical trial.
- General description of composition, manufacture, control of any placebo to be used.
- A copy of all labels and labeling to be provided to each investigator.
CMC Detail vs. Clinical Development Stage
CMC Detail Increases As Clinical Development Progresses

Emphasis on Patient Safety

The amount of information submitted depends on the stage of investigation, testing proposed in humans, duration of testing and whether the information is safety related. The Guidances identify information that would be presented as information amendments & annual updates. An IND for each phase of investigation must include sufficient CMC information to ensure identity, strength, potency, quality & purity of the drug substance and drug product.

Phase I

- Sponsor states if 1) chemistry of drug substance or drug product, or 2) manufacturing of drug substance or drug product pose any potential human risk. If so, this is discussed along with steps to monitor them. Sponsors should describe chemistry/manufacturing differences between drug product for clinical use & drug product used in animal toxicology trials that formed the basis for sponsor's conclusion it’s safe to proceed with the clinical study.

Phase II

- As sponsor documents its product development program, more detailed information is used to establish correlations between data generated in IND studies & the to-be-marketed product & support process controls & specification justification in the NDA. Sponsor carefully assesses changes in manufacturing process/formulation throughout clinical development to determine if changes directly or indirectly affect the safety of the product.

Phase III

- FDA encourages sponsors to meet with the CMC review team before the initiation of Phase 3 clinical trials to discuss issues and protocols that might affect the approvability of the NDA.
## Degree of Drug Substance Detail Required

<table>
<thead>
<tr>
<th>Information</th>
<th>Clinical Development Stage</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Phase 1</strong></td>
<td><strong>Phase 2</strong></td>
</tr>
<tr>
<td><strong>Physical, chemical &amp; biological description</strong></td>
<td>Details on chemical structure to help predict structure of possible metabolites. For peptides; amino acid sequence &amp; peptide map. For DNA products; nucleic acid sequence, DNA melting points &amp; side-chain modifications</td>
</tr>
<tr>
<td><strong>Manufacturer name &amp; address</strong></td>
<td>Addition, deletion or change of any manufacturer of DS used in Phase 1.</td>
</tr>
<tr>
<td><strong>Method of preparation</strong></td>
<td>Updated flow diagram for synthesis or manufacturing process. Need stereo-chemical info on starting/intermediate material. Equipment &amp; monitoring controls. For sterile drugs need more details on sterilization process.</td>
</tr>
<tr>
<td><strong>Acceptable limits &amp; analytical methods to assure identity, strength, quality, purity</strong></td>
<td>Brief description of test methods, proposed acceptable limits, supported by simple analytical data, for clinical trial material. COA. Validation not needed.</td>
</tr>
<tr>
<td><strong>Support for stability during toxicology or clinical studies</strong></td>
<td>Brief description of stability study &amp; test methods to monitor DS stability. Tabular data based on representative material is ok. Detailed stability data or stability protocol not needed.</td>
</tr>
</tbody>
</table>
## Degree of Drug Product Detail Required

<table>
<thead>
<tr>
<th>Information</th>
<th>Clinical Development Stage</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Phase 1</td>
</tr>
<tr>
<td>Components &amp; inactive compounds used in</td>
<td>A list of no more than 1-2 pages of written information should be submitted. The quality</td>
</tr>
<tr>
<td>manufacture</td>
<td>(e.g., NF, ACS) of the inactive ingredients should be cited.</td>
</tr>
<tr>
<td>Components &amp; inactive compounds used in</td>
<td></td>
</tr>
<tr>
<td>manufacture</td>
<td></td>
</tr>
<tr>
<td>Quantitative composition and potential for</td>
<td>Brief summary of composition of the investigational new drug product is needed. Usually,</td>
</tr>
<tr>
<td>variation</td>
<td>information on component ranges is not necessary</td>
</tr>
<tr>
<td>Manufacturer name/address</td>
<td>The full street address(es) of the manufacturer(s) of the clinical trial drug product</td>
</tr>
<tr>
<td></td>
<td>should be submitted.</td>
</tr>
<tr>
<td>Description of manufacturing &amp; packaging</td>
<td>A diagrammatic presentation &amp;brief written description of manufacturing process is needed,</td>
</tr>
<tr>
<td>procedures</td>
<td>including sterilization process for sterile products. Flow diagrams are suggested to present</td>
</tr>
<tr>
<td></td>
<td>information.</td>
</tr>
<tr>
<td>Acceptable limits/analytical methods to</td>
<td>Brief description of proposed limits &amp; test methods. Example: For sterile products,</td>
</tr>
<tr>
<td>assure identity, strength, quality, purity</td>
<td>sterility and non-pyrogenicity. A COA of the clinical batch. Validation data and</td>
</tr>
<tr>
<td></td>
<td>established specifications not needed</td>
</tr>
<tr>
<td>Support for stability during toxicology or</td>
<td>Brief description of stability study &amp; test methods for stability of drug product</td>
</tr>
<tr>
<td>clinical studies</td>
<td>packaged in the proposed container/closure system &amp; storage conditions needed. Preliminary</td>
</tr>
<tr>
<td></td>
<td>tabular data needed</td>
</tr>
<tr>
<td>Composition/manufacture/control of placebo</td>
<td>Diagrammatic, tabular, brief written information</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Copy of all labels provided to investigators</td>
<td>Per 21 CFR 312.6(a). Caution: New Drug - Limited by Federal (United States) law to</td>
</tr>
<tr>
<td></td>
<td>investigational use.</td>
</tr>
</tbody>
</table>

For use only by Affiliates of Regulatory Compliance Associates® Inc. This document contains proprietary information – it must not be reproduced or disclosed to others without prior written approval. Copyright ©2016 Regulatory Compliance Associates Inc. All Rights Reserved.
Summary

• The content of the CMC section of the IND evolves, as product development evolves to better meet the clinical needs of the patient

• The amount of detail required in the CMC section needs to be appropriate to address relevant safety concerns to the patient over the duration of the clinical study

• Sponsors should interact with FDA at each clinical development stage so that the quality of data is progressing in line with what will be needed to obtain an approved NDA
References

- **INDs for Phase 2 and Phase 3 Studies: Chemistry, Manufacturing, and Controls Information**
- **Q2A Text on Validation of Analytical Procedures**
- **Q2B Validation of Analytical Procedures: Methodology**
- **Q3C Impurities: Residual Solvents**
- **Q6A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances**
- **M4: The CTD -- Quality**
Thank you

Sharon Ayd, Ph.D., MBA
Chief Scientific Officer and SVP, Pharmaceuticals
Regulatory Compliance Associates Inc.
10411 Corporate Drive, Suite 102
Pleasant Prairie, WI 53158
s.ayd@rcainc.com